Navigation Links
3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
Date:6/28/2012

SHENYANG, China, June 28, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the State Food and Drug Administration ("SFDA") has approved 3SBio's application to conduct the China arm of the multi-center phase III trial of voclosporin, a new generation calcineurin inhibitor licensed from Isotechnika Pharma Inc. ("Isotechnika") (TSX: ISA).

According to the approved protocol, this will be a phase III, randomized, multi-center, concentration-controlled comparison study on renal transplant patients. Patient enrollment is expected to begin in the third quarter of 2012.  

Further details about voclosporin and 3SBio's strategic partnership with Isotechnika are available in the press releases dated August 24, 2010, September 14, 2010, November 19, 2010 and May 12, 2011 which are archived in the investor relations section of www.3SBio.com.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Safe Harbor Statement

This press release and the comments issued by 3SBio related to SFDA approval of the Company joining global Phase III trial for voclosporin may contain statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. The accuracy of these statements may be impacted by a number of risks factors and uncertainties, including factors related to:  the success and timely completion of phase III trial, and our and our partner's ability to successfully obtain regulatory approvals and commercialize voclosporin on a timely basis; and other risks related to new product development as outlined in 3SBio's filings with the Securities and Exchange Commission. 3SBio does not undertake any obligation to update such forward-looking information, except as required under applicable law.

Investor Contacts

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com

Tom Folinsbee
Director of Investor Relations
3SBio Inc. 
Tel: + 852 8191-6991
ir@3SBio.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Inc. To Present at the DB Access Asia Conference 2012
2. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
3. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
4. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
5. Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
6. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
7. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
8. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
9. ERT Announces Stockholder Approval of Merger
10. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
11. GSK Receives FDA Approval for MenHibrix®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Aug. 15, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Michigan residents. Naloxone is ... retail pharmacy, G-3320 Beecher Road. ... Food and Drug Administration, is intended to block or ... breathing, and loss of consciousness. The medication is often ...
(Date:8/15/2017)... announced today that its fully owned USA -operating ... City Office in Yonkers, New York to ... 2 ) homecare therapy. This new East Coast location has also ... the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New York ...
(Date:8/10/2017)... Colo. , Aug. 10, 2017  Physical Rehabilitation Network ... located in Lakewood, Colorado . The reputable ... Jeff Lipkin , PT, DPT with his staff of four ... University of Pittsburgh and brings over 10 years of experience ... Belmar PT marks the 10th PRN clinic in ...
Breaking Medicine Technology:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... product data and images announced today that it was acquired by Advantage Solutions. ... solution for product information. IX-ONE’s members include the industry’s leading suppliers, brokers, distributors ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... collaborating with a New England student to educate the public on the impact ... 2016 for launching the first-ever National Concussion Awareness Day. , Brooke is working ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... opened their doors. They celebrate 30 years in business this year, and they’re ... up-to-date, inviting, tranquil space to serve their patients. , It stands to ...
(Date:8/16/2017)... , ... August 16, 2017 , ... In a recent ... appearance with diet and exercise. In fact, cellulite can't always be eliminated by diet ... more effective treatment available to select physicians nationwide. Dr. Kenneth Rothaus has recently added ...
Breaking Medicine News(10 mins):